Jun 01, 2020
DelMar Pharmaceuticals to Present Updates of Two Phase 2 Clinical Trials of VAL-083 at the 2020 American Association for Cancer Research Virtual Annual Meeting II
Jan 29, 2020
DelMar Pharmaceuticals Announces Peer-Reviewed Publication of Interim Results of Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma Multiforme
Jul 31, 2019
DelMar Pharmaceuticals Achieves Two-Thirds Enrollment for Phase 2 Clinical Trial of VAL-083 As First-Line Treatment in Newly-Diagnosed MGMT-Unmethylated Glioblastoma MultiForme (GBM)
Jul 24, 2019
DelMar Pharmaceuticals Enrolls First Patient in the Recently-Approved Adjuvant Setting Arm of Phase 2 Study of VAL-083 for the Treatment of MGMT-Unmethylated Glioblastoma Multiforme
Jun 03, 2019
DelMar Provides Clinical Update on VAL-083 from Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated Glioblastoma at a Key Opinion Leader Forum during the American Society of Clinical Oncology (ASCO) Annual Meeting
Feb 20, 2019
DelMar Pharmaceuticals Achieves Halfway Enrollment Point for Phase 2 Clinical Trial of VAL-083 in Newly Diagnosed MGMT-unmethylated GBM
Nov 20, 2018
DelMar Presents Clinical Update on VAL-083 From Ongoing First- and Second-Line Trials in Patients with MGMT-unmethylated GBM at The Society for NeuroOncology Annual Meeting
Nov 19, 2018
Updated Interim Data from Phase 3 Trial of DCVax®-L for Glioblastoma Presented at Society for Neuro-Oncology Conference
Oct 10, 2018
DelMar Announces Further Validation of the Mechanism of Action of VAL-083
Apr 16, 2018
DelMar Pharmaceuticals Announces Multiple Presentations at Annual Meeting of the American Association for Cancer Research
Feb 14, 2018
DelMar Pharmaceuticals Announces Second Quarter Fiscal Year 2018 Financial Results
Nov 21, 2017
DelMar Presents Positive Interim Results from VAL-083 Study in MGMT-unmethylated Recurrent GBM at The Society for NeuroOncology Annual Meeting
Nov 13, 2017
DelMar Pharmaceuticals Announces First Quarter Fiscal Year 2018 Financial Results
Sep 11, 2017
DelMar Pharmaceuticals Initiates Phase 2 Clinical Trial in Newly Diagnosed MGMT-unmethylated Glioblastoma Multiforme
Jun 16, 2017
DelMar Presents Poster of Clinical Research with VAL-083 in Patients with Chemo-resistant Glioblastoma ("GBM") at SNO's Pediatric Neuro-Oncology Basic and Translational Research Conference